A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

Recruiting

Trial ID: NCT06034743

Age - 18 Years-130 Years Gender - All Accepting Healthy Volunteers - No

Purpose

This is a Phase III, multicentre, randomised, double-blinded, placebo-controlled, parallel group study to evaluate the safety, tolerability and effect of 1 or 2 mg baxdrostat versus placebo, administered once daily (QD) orally, on the reduction of systolic blood pressure in approximately 720 participants aged ≥ 18 years with hypertension, despite a stable regimen of 2 antihypertensive agents at baseline, one of which is a diuretic (uncontrolled hypertension); or ≥ 3 antihypertensive agents at baseline, one of which is a diuretic (treatment-resistant hypertension).

Official Title

A Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

Stanford Investigator(s)

Vivek Bhalla, MD
Vivek Bhalla, MD

Associate Professor of Medicine (Nephrology)

Eligibility


Inclusion Criteria:

   - Male or female participants must be ≥ 18 years old

   - Mean sitting systolic blood pressure on automated office blood pressure measurement ≥
   140 mmHg and < 170 mmHg at Screening

   - Fulfil at least 1 of the following 2 criteria:

      1. uHTN subpopulation: have a stable regimen of 2 antihypertensive medications, from
      different therapeutic classes (at least one should be a diuretic), at maximum
      tolerated dose in the judgement of the Investigator

      2. rHTN subpopulation: have a stable regimen of ≥ 3 antihypertensive medications,
      from different therapeutic classes (at least one should be a diuretic), at
      maximum tolerated dose in the judgement of the Investigator

   - Estimated glomerular filtration rate ≥ 45 mL/min/1.73m2 at Screening

   - Serum potassium (K+) level ≥ 3.5 and < 5.0 mmol/L at Screening

   - Randomisation Criterion:

   - Sitting systolic blood pressure on attended automated office blood pressure
   measurement of ≥ 135 mmHg at baseline

Exclusion Criteria:

   - Mean sitting systolic blood pressure on attended automated office blood pressure
   measurement ≥ 170 mmHg at Randomisation

   - Mean seated diastolic blood pressure on attended automated office blood pressure
   measurement ≥ 110 mmHg at Randomisation

   - Serum sodium level < 135 mmol/L at Screening

   - Has the following known secondary causes of hypertension: renal artery stenosis,
   uncontrolled or untreated hyperthyroidism, uncontrolled or untreated hypothyroidism,
   pheochromocytoma, Cushing's syndrome, aortic coarctation

   - New York Heart Association functional heart failure class IV at Screening

   - Persistent atrial fibrillation

View More
View Less

Intervention(s):

drug: Baxdrostat

drug: Placebo

Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305

©2024 Stanford Medicine